



SERNOVA CORP.

**INTERIM CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE THREE AND SIX MONTHS ENDED
APRIL 30, 2018 AND 2017**

**(Expressed in Canadian Dollars)
(Unaudited)**

700 Collip Circle
The Stiller Centre, Suite 114
London, ON
N6G 4X8
www.sernova.com

These unaudited interim condensed consolidated financial statements of Sernova Corp. (the "Company") have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these interim financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

SERNOVA CORP.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AS AT
(Expressed in Canadian Dollars)
(Unaudited)

	Note	April 30, 2018	October 31, 2017
ASSETS			
Current assets			
Cash and cash equivalents		\$ 1,381,630	\$ 2,627,513
Marketable securities		1,011,096	1,004,374
Amounts receivable	4	157,434	641,372
Prepaid expenses		<u>26,528</u>	<u>39,785</u>
Total current assets		<u>2,576,688</u>	<u>4,313,044</u>
Non-current assets			
Property and equipment, net	5	<u>321,749</u>	<u>238,474</u>
Total non-current assets		<u>321,748</u>	<u>238,474</u>
Total assets		<u>\$ 2,898,437</u>	<u>\$ 4,551,518</u>
LIABILITIES			
Current liabilities			
Accounts payable and accrued liabilities	6	\$ 511,924	\$ 463,466
Deferred government assistance	10	<u>-</u>	<u>437,600</u>
Total current liabilities		<u>511,922</u>	<u>901,066</u>
EQUITY			
Common shares	7	33,853,874	33,673,521
Warrants	7	993,360	993,360
Contributed surplus		4,084,189	3,775,776
Deficit		<u>(36,544,910)</u>	<u>(34,792,205)</u>
Total equity		<u>2,386,513</u>	<u>3,650,452</u>
Total liabilities and equity		<u>\$ 2,898,437</u>	<u>\$ 4,551,518</u>
Nature and continuance of operations (Note 1)			
Deferred grants, commitments and contingencies (Note 10)			

See accompanying notes to the interim condensed consolidated financial statements.

SERNOVA CORP.**INTERIM CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30,
(Expressed in Canadian Dollars)
(Unaudited)**

	Note	Three Months Ended April 30,		Six Months Ended April 30,	
		2018	2017	2018	2017
EXPENSES					
Research and development	9	\$ 524,518	\$ 389,425	\$ 1,021,524	\$ 452,947
General and administrative	9	<u>464,850</u>	<u>285,578</u>	<u>737,037</u>	<u>541,799</u>
Total operating expenses		<u>989,368</u>	<u>675,003</u>	<u>1,758,561</u>	<u>994,746</u>
Finance income		(7,660)	(12,278)	(17,035)	(31,282)
Finance costs		2,052	4,077	5,411	8,042
Foreign exchange loss (gain)		<u>2,590</u>	<u>(28,370)</u>	<u>5,768</u>	<u>(15,551)</u>
Net finance income		<u>(3,018)</u>	<u>(36,571)</u>	<u>(5,856)</u>	<u>(38,791)</u>
Net loss and comprehensive loss for the period		\$ 986,350	\$ 638,432	\$ 1,752,705	\$ 955,955
Weighted average number of common shares outstanding for the period					
		159,893,223	157,603,670	159,691,413	156,835,605
Basic and diluted loss per common share					
		\$ 0.01	\$ 0.00	\$ 0.01	\$ 0.01

See accompanying notes to the interim condensed consolidated financial statements.

SERNOVA CORP.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30,
(Expressed in Canadian Dollars)
(Unaudited)

	Six Months Ended April 30,	
	2018	2017
CASH PROVIDED BY (USED IN):		
OPERATING ACTIVITIES		
Loss for the period	\$ (1,752,705)	\$ (955,955)
Adjustments for items not affecting cash:		
Depreciation of property and equipment	31,757	13,078
Share-based compensation	315,729	224,287
Interest accrued on short-term investments	(6,722)	(3,320)
Contributions	(437,600)	(475,427)
Changes in non-cash working capital balances:		
Amounts receivable	152,168	74,903
Prepaid expenses	13,257	33,877
Accounts payable and accrued liabilities	48,457	6,645
Net cash used in operating activities	<u>(1,635,659)</u>	<u>(1,081,912)</u>
INVESTING ACTIVITIES		
Marketable securities, net	-	500,000
Acquisition of property and equipment	<u>(115,032)</u>	<u>(23,823)</u>
Net cash used in investing activities	<u>(115,032)</u>	<u>476,177</u>
FINANCING ACTIVITIES		
Issue of common shares on exercise of warrants	162,960	-
Issue of common shares on exercise of stock options	10,078	470,500
Grants	<u>331,770</u>	<u>249,611</u>
Net cash provided by financing activities	<u>504,808</u>	<u>720,111</u>
Change in cash and cash equivalents during the period	(1,245,883)	114,376
Cash and cash equivalents, beginning of period	<u>2,627,513</u>	<u>5,199,451</u>
Cash and cash equivalents, end of period	<u>\$ 1,381,630</u>	<u>\$ 5,313,827</u>
Supplementary cash flow information:		
Property and equipment acquired through accounts payable and accrued liabilities	\$ -	\$ 77,788

See accompanying notes to the interim condensed consolidated financial statements.

SERNOVA CORP.**INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

	Common Shares		Warrants		Contributed Surplus	Deficit	Total
	Number	(Note 7) Amount	Number	(Note 7) Amount			
Balance, October 31, 2017	159,374,498	\$ 33,673,521	26,110,739	\$ 993,360	\$ 3,775,776	\$ (34,792,205)	\$ 3,650,452
Loss and comprehensive loss for the period	–	–	–	–	–	(1,752,705)	(1,752,705)
Transactions with owners of the Company, recognized directly in equity							
Exercise of stock options	53,125	17,393	–	–	(7,315)	–	10,078
Exercise of warrants	465,600	162,960	(465,600)	–	–	–	162,960
Warrants expired unexercised	–	–	(8,788,889)	–	–	–	–
Share-based compensation	–	–	–	–	315,728	–	315,728
Balance, April 30, 2018	159,893,223	\$ 33,853,874	16,856,250	\$ 993,360	\$ 4,084,189	\$ (36,544,910)	\$ 2,386,513
Balance, October 31, 2016	156,679,498	\$ 32,902,583	26,216,362	\$ 993,360	\$ 3,635,753	\$ (32,152,726)	\$ 5,378,970
Loss and comprehensive loss for the period	–	–	–	–	–	(955,955)	(955,555)
Transactions with owners of the Company, recognized directly in equity							
Exercise of stock options	2,695,000	931,700	–	–	(461,200)	–	470,500
Share-based compensation	–	–	–	–	224,287	–	224,287
Balance, April 30, 2017	159,374,498	\$ 33,834,283	26,216,362	\$ 993,360	\$ 3,398,840	\$ (33,108,681)	\$ 5,117,802

See accompanying notes to the interim condensed consolidated financial statements.

SERNOVA CORP.**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

1. NATURE AND CONTINUANCE OF OPERATIONS

Sernova Corp. (the “Company”) is a regenerative medicine company engaged in the research and development of its proprietary Cell Pouch™ and associated technologies including immune-protected therapeutic cells. The Company is focused on developing a commercially-viable treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted, prevascularized and scalable medical device (the Cell Pouch™), protected from immune system attack.

Sernova Corp. was incorporated under the Company Act (British Columbia) on August 19, 1998. Effective May 29, 2001, the Company was continued under the Canada Business Corporations Act.

The Company’s head office is located at 700 Collip Circle, Suite 114, London, Ontario, N6G 4X8. The Company’s registered address is Suite 1500 – 1055 West Georgia Street, Vancouver, British Columbia, V6E 2N7. The Company is listed on the TSX Venture Exchange under the symbol SVA and is also listed on the OTCQB Venture Market under the symbol SEOVF.

These interim condensed consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) that are applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business for the foreseeable future. The Company has experienced operating losses and cash outflows from operations since its inception, and accordingly, it will require ongoing financing in order to continue its research and development activities. The ability of the Company to continue as a going concern in the long-term depends upon its ability to develop profitable operations and to continue to raise adequate financing. The Company will seek new funding from additional equity financings and/or licensing agreements and collaborations with development partners. Management believes that the Company has sufficient working capital to maintain its operations for at least the next twelve months.

2. BASIS OF PRESENTATION**(a) Statement of compliance**

These interim condensed consolidated financial statements for the three and six months ended April 30, 2018 and 2017 were prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting* (“IAS 34”) as issued by the International Accounting Standards Board (“IASB”).

The same accounting policies and methods of computation were followed in the preparation of these interim condensed consolidated financial statements as were followed in the preparation of the annual consolidated financial statements for the years ended October 31, 2017 and 2016, which were prepared in accordance with IFRS as issued by the IASB. Any subsequent changes to IFRS or their interpretation, that are given effect in the Company’s annual audited consolidated financial statements for the year ending October 31, 2018, could result in a restatement of these unaudited interim condensed consolidated financial statements. These interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements. Accordingly, these interim condensed consolidated financial statements for the three and six months ended April 30, 2018 and 2017 should be read together with the annual consolidated financial statements for the years ended October 31, 2017 and 2016.

The preparation of interim condensed consolidated financial statements in accordance with IAS 34 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company’s accounting policies. These interim condensed consolidated financial statements were authorized for issuance by the Company’s Board of Directors on June 29, 2018.

SERNOVA CORP.

**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

2. BASIS OF PRESENTATION (cont'd...)

(b) Basis of measurement:

These interim condensed consolidated financial statements have been prepared on a historical cost basis, except for financial instruments classified as financial instruments at fair value through profit or loss, which are stated at their fair value.

(c) Functional and presentation currency

These interim condensed consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company and its wholly-owned and controlled subsidiaries.

(d) Use of significant estimates and assumptions

The preparation of these interim condensed consolidated financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies, the reported amounts of assets, liabilities and expenses, as well as the Company's ability to continue as a going concern. The estimates and assumptions made are continually evaluated and have been based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Such estimates and assumptions are inherently uncertain. Actual results could differ materially from these estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised and may impact future periods.

Management has applied significant estimates and assumptions to the following:

Valuation of share-based compensation

The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected: option life, volatility, risk-free interest rate, forfeiture rates, stock option exercise behaviours, dividend yield and corporate performance. Changes in these assumptions affect the fair value estimate for share-based compensation.

3. SIGNIFICANT ACCOUNTING POLICIES

New standards, amendments and interpretations adopted during 2018

IFRS 9, Financial Instruments

As at November 1, 2017, the Company adopted IFRS 9, Financial Instruments (IFRS 9). The Company has elected to not restate comparative periods in the year of initial application of IFRS 9 relating to the transition for classification, measurement and impairment. As a result, the comparative information provided continues to be accounted for on a basis consistent with those followed in the most recent annual consolidated financial statements.

IFRS 9 replaces the provisions of IAS 39 that relate to the recognition, classification and measurement of financial assets and financial liabilities, derecognition of financial instruments, impairment of financial assets and hedge accounting. IFRS 9 also significantly amends other standards dealing with financial instruments such as IFRS 7, Financial Instruments: Disclosures.

SERNOVA CORP.**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

Classification and Measurement of Financial Instruments

The Company assessed the classification and measurement of the financial instruments it held at the date of initial application of IFRS 9 (November 1, 2017) and has classified its financial instruments into the appropriate IFRS 9 categories. There were no changes to the carrying value of the Company's financial instruments resulting from this reclassification and accordingly there was no impact to the Company's opening balance of deficit as at November 1, 2017 as a result of the adoption of IFRS 9.

At initial recognition, the Company measures a financial instrument at its fair value plus, in the case of a financial instrument not at fair value through profit (loss), transaction costs that are directly attributable to the acquisition of the financial instrument. Transaction costs of financial instruments carried at fair value through profit (loss) are expensed in profit (loss).

Subsequent measurement of financial assets depends on the Company's business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories in which the Company classifies its financial instruments:

- Amortized cost: Financial assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. Finance income from these financial instruments is recorded in net income (loss) using the effective interest rate method.
- Fair value through other comprehensive income (FVOCI): Financial instruments that are held for collection of contractual cash flows and for selling the financial instruments, where the financial instruments' cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses which are recognized in net income (loss). When the financial instrument is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to net income (loss).
- Fair value through profit (loss) (FVTPL): Financial instruments that do not meet the criteria for amortized cost or FVOCI are measured at fair value through profit (loss). A gain or loss on a financial instrument that is subsequently measured at fair value through profit (loss) and is not part of a hedging relationship is recognized in net income (loss) and presented net in comprehensive income (loss) in the period in which it arises.

Financial liabilities are subsequently measured at amortized cost using the effective interest method or at FVTPL. Financial liabilities are subsequently measured as FVTPL when the financial liability is (i) contingent consideration of an acquirer in a business combination, (ii) held for trading, or (iii) it is designated as FVTPL if eligible.

Reclassifications of Financial Instruments on Adoption of IFRS 9

On the date of initial application, November 1, 2017, the financial instruments of the Company were as follows, with any reclassifications noted:

	Measurement	
	Original (IAS 39)	New (IFRS 9)
Financial Assets		
Cash and cash equivalents	FVTPL	Amortized cost
Marketable securities	FVTPL	Amortized cost
Financial Liabilities		
Accounts payable and accrued liabilities	Amortized cost	Amortized cost

SERNOVA CORP.**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

The Company's marketable securities include guaranteed investment certificates (GICs) held by the Company which were reclassified from the fair value through profit (loss) measurement category to amortized cost. At the date of initial application, the Company's business model meets the criteria for amortized cost. The Company intends to hold the GICs to maturity to collect contractual cash flows and these cash flows consist solely of payments of principal and interest on the principal amount outstanding.

Impairment of Financial Assets

The Company's cash and cash equivalents and marketable securities are subject to IFRS 9's new expected credit loss model which results in a revision to its impairment methodology. Marketable securities at amortized cost are considered to be low risk, and therefore the impairment provision is determined using a twelve month expected credit loss basis. There was no impact to the Company's opening balance of deficit as a result of the change in impairment methodology.

New standards and interpretations not yet effective*IFRS 15 Revenue from Contracts with Customers*

In May 2014, the IASB issued IFRS 15 *Revenue from Contracts with Customers* ("IFRS 15") which covers principles for reporting about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is required to be applied for years beginning on or after January 1, 2018. The Company has assessed there is no impact of this standard on the Company's consolidated financial statements, and accordingly these interim condensed financial statements have been prepared in accordance with IFRS 15 *Revenue from Contracts with Customers*.

IFRS 16 Leases

In January 2016, the IASB issued IFRS 16 *Leases* ("IFRS 16"), its new lease standard that requires lessees to recognize assets and liabilities for most leases on the statement of financial position. Lessees applying IFRS 16 will have a single accounting model for all leases, with certain exemptions. Lessor accounting is substantially unchanged. The new standard will be effective from January 1, 2019 with limited early application permitted. The Company is currently monitoring the development of this standard and assessing the impact that adoption of this standard may have on the consolidated financial statements.

Other accounting standards or amendments to existing accounting standards that have been issued, but have future effective dates, are either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements.

4. AMOUNTS RECEIVABLE

As at	April 30, 2018	October 31, 2017
Government programs receivable	\$ 30,591	\$ 240,981
Grants receivable (Note 10)	-	331,770
Tax credits receivable	126,343	68,621
Other receivables	500	-
	<u>\$ 157,434</u>	<u>\$ 641,372</u>

SERNOVA CORP.**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

5. PROPERTY AND EQUIPMENT

	Computer and Office Equipment	Laboratory Equipment	Manufacturing Equipment	Total
Cost				
Balance, October 31, 2017	77,091	127,548	105,098	309,737
Additions	<u>9,371</u>	<u>105,661</u>	<u>-</u>	<u>115,032</u>
Balance, April 30, 2018	\$ 86,462	\$ 233,209	\$ 105,098	\$ 424,769
Accumulated depreciation				
Balance, October 31, 2017	35,413	34,098	1,752	71,263
Depreciation	<u>5,435</u>	<u>16,246</u>	<u>10,076</u>	<u>31,757</u>
Balance, April 30, 2018	\$ 40,848	\$ 50,344	\$ 11,828	\$ 103,020
Net carrying amounts				
October 31, 2017	\$ 41,678	\$ 93,450	\$ 103,346	\$ 238,474
April 30, 2018	\$ 45,614	\$ 182,865	\$ 93,270	\$ 321,749

6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

As at	April 30, 2018	October 31, 2017
Accounts payable	\$ 286,428	\$ 182,860
Accrued liabilities	175,496	216,086
Due to related parties (Note 8)	<u>50,000</u>	<u>64,520</u>
	\$ 511,924	\$ 463,466

7. COMMON SHARES AND WARRANTS**(a) Authorized**

Unlimited number of common shares, without par value.

(b) Share capital transactions – six months ended April 30, 2018 and 2017

For the six months ended April 30, 2018, 53,125 stock options were exercised for gross cash proceeds of \$10,078 and 465,600 warrants were exercised for gross cash proceeds of \$162,960. During the same period 676,875 stock options expired and 8,788,889 warrants expired.

For the six months ended April 30, 2017, 2,695,000 stock options were exercised for gross cash proceeds of \$470,500. During the same period 1,177,500 stock options were cancelled/forfeited.

SERNOVA CORP.**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

7. COMMON SHARES AND WARRANTS (cont'd ...)**(c) Warrants**

The following table summarizes warrants outstanding as at April 30, 2018:

	Number of Warrants	Exercise Price	Expiry Date
Warrants			
	8,133,650	0.35	June 27, 2018
	<u>8,722,600</u>	0.35	June 30, 2018
	<u>16,856,250</u>		

All warrants are exercisable on issuance. The changes in the number of warrants outstanding during the six months ended April 30, 2018 and 2017 were as follows:

	2018		2017	
	Number of Warrants	Weighted Average Exercise Price	Number of Warrants	Weighted Average Exercise Price
Balance outstanding, beginning of period	26,110,739	\$ 0.33	26,216,362	\$ 0.33
Expired	(8,788,889)	0.30	-	-
Exercised	(465,600)	0.35	-	-
Balance outstanding, end of period	16,856,250	\$ 0.35	26,216,362	\$ 0.33

(d) 2015 Incentive Plan

The Company has a 2015 Incentive Plan (the "Plan"), the terms of which were most recently approved by shareholders of the Company on April 25, 2018. Under the Plan the Board of Directors may grant stock options to directors, officers, employees or consultants of the Company and deferred share units ("DSUs") to directors and officers of the Company up to an aggregate of 15% of the Company's issued and outstanding common shares. The number of common shares reserved for issuance as DSU's under the Plan is fixed at a maximum of 4,796,797, representing 3% of the Common Shares at the date hereof.

During the financial year ended October 31, 2017, the Corporation granted 239,778 DSUs to certain directors of the Corporation. The Board also approved an amendment to the Company's Option Plan & Deferred Share Unit Plan (the "Incentive Plan") to increase the number of DSUs available by 660,222 to a maximum of 1,975,000. These additional DSUs were conditionally approved and granted subject to the Company obtaining shareholder approval and TSX Venture Exchange approval ("Exchange approval").

On March 19, 2018, the Board approved two further amendments to the Incentive Plan, subject to shareholder and Exchange approval, being: (a) an increase to 15% of the rolling number maximum of Common Shares available for reserve under the Incentive Plan for exercise of Options pursuant to the Option Plan component of the Incentive Plan; and (b) a further amendment to the DSU Plan component of the Incentive Plan to further increase the number of DSUs available by an additional 2,821,797 DSUs to a maximum fixed number total of 4,796,797 DSUs.

SERNOVA CORP.**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

7. COMMON SHARES AND WARRANTS (cont'd ...)**(d) 2015 Incentive Plan (cont'd ...)**

All of the proposed amendments to the Incentive Plan were approved by shareholders of the Company at the Annual General Meeting but have not yet been approved by the TSX Venture Exchange. No additional options or DSUs were granted after the financial year ended October 31, 2017 and to the date of these financial statements.

Options granted under the Plan have lives of up to ten years from the date of grant. The vesting schedule of all granted options is determined at the discretion of the Board. According to the terms of the Plan, the exercise price of any options granted must be in accordance with the policies of the TSX Venture Exchange.

The following table summarizes options outstanding as at April 30, 2018:

	Number of Options	Exercise Price	Expiry Date
Options	313,600	\$ 0.350	July 4, 2018
	1,750,000	\$ 0.150	January 27, 2019
	150,000	\$ 0.150	February 11, 2019
	1,525,000	\$ 0.260	June 25, 2025
	2,250,000	\$ 0.225	March 14, 2026
	250,000	\$ 0.260	November 14, 2026
	<u>3,580,000</u>	\$ 0.250	August 14, 2027
	9,818,600		

As at April 30, 2018, there were 9,818,600 options outstanding, representing 6.1% of the Company's issued and outstanding common shares (October 31, 2017 – 10,548,600 options outstanding representing 6.6%).

Changes in the number of options outstanding during the six months ended April 30, 2018 and 2017, were as follows:

	2018		2017	
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price
Balance outstanding, beginning of period	10,548,600	\$ 0.23	10,436,100	\$ 0.19
Granted	-	-	250,000	0.26
Cancelled/Forfeited	(676,875)	0.24	(1,177,500)	0.22
Exercised	(53,125)	0.19	(2,695,000)	0.175
Balance outstanding, end of period	9,818,600	\$ 0.23	6,813,600	\$ 0.22
Options exercisable, end of period	5,340,663	\$ 0.22	4,387,137	\$ 0.21

SERNOVA CORP.**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

The following table reflects details of the stock options outstanding by range of exercise prices as at April 30, 2018:

Range of Exercise Prices	Number Outstanding	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Exercise Price
\$ 0.14 to \$ 0.18	1,900,000	0.7	\$ 0.15	1,900,000	\$ 0.15
\$ 0.22 to \$ 0.26	7,605,000	8.4	0.24	3,127,063	0.24
\$ 0.35	313,600	0.2	0.35	313,600	0.35
\$ 0.14 to \$ 0.35	9,818,600	6.7	\$ 0.23	5,340,663	\$ 0.22

The Company's Plan allows for the issuance of DSUs to Directors and Officers of the Company in the form of a cash payment or issuance of shares at the time the DSU holder leaves the Company. Since the method of settlement of the DSUs is at the discretion of the Company under the plan, it has been accounted for as an equity settled plan. On June 25, 2015, March 14, 2016 and August 14, 2017, the Company issued 625,000, 450,000 and 239,778 DSUs to directors, respectively. The DSUs vest over a three-year period after the date of grant. Up to April 30, 2018 873,292 DSUs had vested.

8. RELATED PARTY TRANSACTIONS

The key management personnel of the Company are the Directors, the President and Chief Executive Officer and the Chief Financial Officer. Amounts due to related parties, including amounts due to key management personnel, at the period-end are unsecured, interest free and settlement generally occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. Included in accounts payable and accrued liabilities at April 30, 2018 was \$50,000 due to key management personnel (October 31, 2017 – \$64,520).

Compensation to key management personnel for the three and six months ended April 30, 2018 and 2017, was as follows:

	Three months ended April 30,		Six months ended April 30,	
	2018	2017	2018	2017
Salaries, benefits and consulting fees	\$ 160,644	\$ 115,178	\$ 234,541	\$ 211,513
Director fees and benefits	24,985	24,984	50,481	49,969
DSU's issued for director compensation	63,436	21,680	78,096	48,719
Share-based compensation	<u>51,652</u>	<u>17,174</u>	<u>108,526</u>	<u>41,215</u>
Total	\$ 300,717	\$ 179,016	\$ 471,644	\$ 351,416

SERNOVA CORP.**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

9. STATEMENT OF LOSS AND COMPREHENSIVE LOSS SUPPLEMENTARY INFORMATION

Components of the research and development expenses for the three and six months ended April 30, 2018 and 2017, were as follows:

	Three months ended April 30, 2018		Six months ended April 30, 2018	
Employee costs, supplies and contract payments	\$ 356,807	\$ 441,191	\$ 697,142	\$ 735,203
Manufacturing costs	204,468	29,028	415,542	29,028
Patent fees and costs	49,933	51,827	185,258	83,612
Depreciation of property and equipment	15,355	6,460	30,670	12,920
Share-based compensation	76,324	50,020	160,512	119,509
Contributions and tax credits	<u>(178,369)</u>	<u>(189,101)</u>	<u>(467,600)</u>	<u>(527,325)</u>
Total research and development expenses	\$ 524,518	\$ 389,425	\$ 1,021,524	\$ 452,947

Components of the general and administrative expenses for the three and six months ended April 30, 2018 and 2017, were as follows:

	Three months ended April 30, 2018		Six months ended April 30, 2018	
Employee costs and consulting fees	\$ 62,400	\$ 85,662	\$ 124,838	\$ 145,421
Professional fees	163,108	25,136	187,378	41,048
Director fees and benefits	24,985	26,494	50,481	51,479
Investor relations	52,267	59,726	98,726	111,355
Travel and other costs	62,157	42,118	119,311	87,559
Depreciation of property and equipment	549	79	1,087	158
DSU's issued for director compensation	63,436	21,680	78,096	48,719
Share-based compensation	<u>35,948</u>	<u>24,682</u>	<u>77,120</u>	<u>56,060</u>
Total general and administrative expenses	\$ 464,850	\$ 285,577	\$ 737,037	\$ 541,799

10. DEFERRED GRANTS, COMMITMENTS AND CONTINGENCIES

In December 2015, the Company was awarded a €5.6 million (approximately \$8.5 million) non-dilutive grant by the European Commission's Horizon 2020 program, as part of a consortium. The Company expects to receive total funding in the amount of €944,178 (approximately \$1.4 million), representing its portion of the grant, based upon the terms of the grant agreement. In January 2016, the Company received an initial funding payment related to the grant in the amount of €566,507 (\$873,213). In November 2017, the Company received an interim payment in the amount of €226,603 (\$331,770). Expenditures incurred by the Company related to the grant to April 30, 2018 amounted to \$1,283,817. By participating in the HemAcure consortium and accepting grant funding, the Company has committed to perform certain product development activities, as outlined in the grant agreement with the European Commission's Horizon 2020 program. Amounts claimed by the Company against the grant will be subject to an audit by the European Commission.

In July 2016, the Company was awarded up to US\$2.45 million (approximately \$3.2 million) grant under an agreement with JDRF Therapeutics Fund, LLC ("JDRF"). The grant supports a human clinical trial of Sernova's Cell Pouch™ for treatment of patients with type 1 diabetes at a major transplantation center in the United States. In August 2016, the Company received an initial funding payment from JDRF in the amount of US\$367,768 (\$480,783). Pursuant to the agreement with JDRF, the Company has committed to perform certain clinical trial activities and to use commercially reasonable efforts to introduce a diabetes product into the US market. Further, the Company is required

SERNOVA CORP.**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2018 AND 2017**

(Expressed in Canadian Dollars)

(Unaudited)

to pay royalties to JDRF on any future net sales received by the Company from a diabetes product or in certain future license or disposition transactions limited to a certain percentage of funds received over time up to a prescribed limit related to the amount of the grant funding.

In October 2016, the Company entered into a collaboration with an international pharmaceutical company to study Sernova's Cell Pouch™ in a large animal diabetes model. The collaboration involves the study of safety, survival and efficacy of locally immune protected therapeutic cells in our Cell Pouch™ in proof of concept studies with the goal to establish a future development and commercial partnership. This agreement included 50% cost sharing for the agreed studies. A payment in the amount of US\$185,778 (\$249,611) was received in December 2016.

The Company expects to pay certain future costs related to its clinical trials. Such payments are expected to include the cost of clinical staff and overhead thereon, trial insurance, and may include travel and a portion of drug or procedure-related expenses or transplantation expenses not covered by insurance. The total expected future payments will be impacted by such factors as the rate of enrollment, the location in which the patient resides and the specifics of patient insurance.

The Company entered into a three year lease effective September 1, 2017. Notwithstanding the term, the Company has the right to terminate the lease after the first anniversary by providing 90 days' written notice. As at April 30, 2018 gross minimum payments, to the earliest termination date, amounted to \$66,273.

11. EVENTS AFTER THE REPORTING PERIOD

On June 25, 2018, the Company announced a \$1 million institutional lead order in connection with a proposed private placement of up to \$2 million special warrants ("Special Warrants") of the Company at a price of \$0.25 per Special Warrant.

Each Special Warrant will convert, for no additional consideration, into one Unit ("Unit") of the Company. Each Unit will consist of one common share and one common share purchase warrant ("Warrant") of the Company. Each Warrant will be exercisable into one share at \$0.35 per share for a period of 24 months, subject to abridgement of the exercise period if the 20-day volume weighted price of the Company's shares exceeds \$0.50 per share.